Issue link: https://www.e-digitaleditions.com/i/1514395
Inhalation January 2024 7 P/L Biomedical 10882 Stonington Avenue Fort Myers, FL 33913, United States Tel. +1 239 244 1448 Contact: Lee Leichter E-mail: leichter@plbiomedical.com P/L Biomed ic a l is recogni z ed for prov id ing up -to -d ate knowledge and experience to assist in critical areas related to development, registration and compliance of drug delivery combination products. Respidex, LLC PO Box 218 Dennis, MA 02638, United States Tel. +1 510 731 8820 and +61 438 550 705 Contact: Igor Gonda Email: igonda@respidex.com Since 2018, Respidex LLC has provided a broad range of con- sulting services on a variety of tactical and strategic aspects of research, development and commercialization of pharmaceu- tical products, leveraging decades of experiences by its founder and CEO, Dr. Igor Gonda, particularly with orally inhaled and nasally delivered therapies. Wallder Limited Vectis House, 7 Nightingale Lane St. Albans, AL1 1DX, United Kingdom Tel. +44 1727 822855 Contact: David Wallder E-mail info@wallder.com Website: www.wallder.com Our métier is Inhalation. Board/Senior Management, SAB recruitment. All areas: propellants and low GWP alternatives, tooling/molding through the finished drug/device combination within big pharma. www.inhalationmag.com Designed to provide educational content, the Inhalation 1-2-3 e-newsletter includes a supplier's perspective on industry issues, highlights technical articles from the magazine and previews industry conferences. Please watch for it in your inbox every other month. Sign up now by emailing your name, company name and email address to subscriptions@inhalationmag.com.